These mutations were chosen from those documented in the COSMIC (catalog of somatic mutations in cancer) database (Tate et al, 2019), as well as from mutations found from targeted sequencing of the GLI1 gene in advanced or drug resistant basal cell carcinomas (Table S1). This evidence concerns the gene GLI1 and cancer.